Could q-CAR Redefine Drug Discovery?
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.
AI-designed bacteriophages show how genome models could create new antibacterial therapies while forcing pharma to rethink biological AI governance and biosecurity.
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.